Characteristics | Cohort 1: SEER | Cohort 2: FDUSCC | Cohort 3: Publicly available cases | Cohort 4: Publicly available NCT cases | ||||
---|---|---|---|---|---|---|---|---|
 | N = 67,932 | % | N = 2,338 | % | N = 837 | % | N = 483 | % |
Age, years (IQR) | 61 (51–70) |  | 53 (45–60) |  | 55 (45–65) |  | 50 (42–58) |  |
Tumor size | Â | Â | Â | Â | Â | Â | Â | Â |
 T0–1 | 42,281 | 62.2 | 1,132 | 48.4 | 155 | 38.8 | 33 | 6.8 |
 T2 | 20,253 | 29.8 | 1,004 | 42.9 | 210 | 52.6 | 244 | 50.5 |
 T3–4 | 5,398 | 7.9 | 202 | 8.6 | 34 | 8.5 | 206 | 42.7 |
Lymph nodes | Â | Â | Â | Â | Â | Â | Â | Â |
 Negative | 47,078 | 69.3 | 1,168 | 50.2 | 285 | 47.3 | 150 | 31.1 |
 Positive | 20,854 | 30.7 | 1,161 | 49.8 | 317 | 52.7 | 333 | 68.9 |
Grade | Â | Â | Â | Â | Â | Â | Â | Â |
 I | 17,172 | 26.2 | 39 | 1.7 | 102 | 13.2 | 31 | 6.8 |
 II | 29,359 | 44.7 | 1,610 | 68.9 | 244 | 31.6 | 173 | 38.1 |
 III and UD | 19,129 | 29.1 | 689 | 29.5 | 426 | 55.2 | 250 | 55.1 |
Subgroup | Â | Â | Â | Â | Â | Â | Â | Â |
 ER+/PgR+ | 50,679 | 74.6 | 1,686 | 72.1 | 391 | 46.7 | 216 | 44.7 |
 ER+/PgR– | 7,075 | 10.4 | 177 | 7.6 | 130 | 15.5 | 72 | 14.9 |
 ER–/PgR+ | 561 | 0.8 | 34 | 1.5 | 36 | 4.3 | 17 | 3.5 |
 ER–/PgR– | 9,617 | 14.2 | 441 | 18.9 | 280 | 33.5 | 178 | 36.9 |
Median follow-up, months (IQR) | 11 (5–17) |  | 37 (25–50) |  | 49 (20–72) |  | 36 (21–49) |  |